Epidiolex FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved June 25, 2018)
Brand name: Epidiolex
Generic name: cannabidiol
Dosage form: Oral Solution
Company: GW Pharmaceuticals plc
Treatment for: Seizures associated with Lennox-Gastaut Syndrome, Dravet syndrome, or Tuberous Sclerosis Complex
Epidiolex (cannabidiol) is a prescription pharmaceutical formulation of highly-purified, marijuana plant-derived cannabidiol (CBD) indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.
Development timeline for Epidiolex
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.